The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

A worker leaves the AstraZeneca research facility in Loughborough,
A worker leaves the AstraZeneca research facility in Loughborough,
(© Darren Staples / Reuters/Darren Staples/REUTERS)

SUBSCRIBERS ONLY

A pain relief regimen for AstraZeneca

There was a sense of “don’t look now” about AstraZeneca’s full-year results on Thursday. The important date for investors in the U.K. pharmaceutical group is March 21, when new chief executive officer Pascal Soriot will present his ideas for restoring the ailing company’s fortunes.

In truth, the 2012 numbers were not as terrible as they might have been. But they were enough to remind everyone of how tough a task the restoration will be. A steep drop in sales and earnings per share showed the damage wrought by expiring patents, while investors were not even thrown the bones of a dividend increase or share buyback.